Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

Dale and colleagues compared lipodystrophy-related adverse events in the START I and II trials. The trials compared AZT + 3TC + indinavir (IDV), d4T + 3TC + IDV, and d4T + ddI + IDV regimens, analyzing all adverse events, including discontinuation due to changes in body mass index, weight, and non-fasting glucose and triglycerides.

The two d4T arms (n = 202) were combined and compared against the AZT arm (n = 205). Among patients in the d4T arm, 6% showed lipodystrophy related events, 3.5% had grade 3 or 4 elevations in non-fasting glucose levels, and 4% had grade 3 or 4 non-fasting hypertriglyceridemia. Patients receiving AZT had a 7% incidence of lipodystrophy-related events, a 4.4% rate of grade 3 or 4 elevated non-fasting glucose levels, and a 2.9% incidence of grade 3 or 4 non-fasting hypertriglyceridemia. No significant difference in changes in body mass index or in the development of lipodystropy related events were reported between the two groups. However, because the investigators were not specifically asked to report changes in fat distribution, changes in these characteristics may have been underreported.

Abstract: Incidence of Lipodystrophy on START (Selection of Thymidine Analog Regimen Therapy) Studies
Authored by: E. Dale, J. Mauney, K. Uffelman, M. Stevens, and R. Grosso



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement